Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Immunome Inc shares valued at $46,900 were purchased by BIENAIME JEAN JACQUES on Jun 03 ’25. At $9.38 per share, BIENAIME JEAN JACQUES acquired 5,000 shares. The insider’s holdings grew to 36,415 shares worth approximately $0.33 million following the completion of this transaction.
Also, BIENAIME JEAN JACQUES purchased 7,800 shares, netting a total of over 60,684 in proceeds. Following the buying of shares at $7.78 each, the insider now holds 31,415 shares.
Before that, SIEGALL CLAY B had added 137,100 shares to its account. In a trade valued at $999,459, the President and CEO bought Immunome Inc shares for $7.29 each. Upon closing the transaction, the insider’s holdings increased to 137,100 shares, worth approximately $7.28 million.
As published in their initiating research note from Lake Street on April 02, 2025, Immunome Inc [IMNM] has been a Buy and the price target has been revised to $23. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in early November. As of May 31, 2024, Piper Sandler has initiated its “an Overweight” rating for IMNM. Earlier on April 30, 2024, JP Morgan initiated its rating. Their recommendation was “an Overweight” for IMNM stock.
Analyzing IMNM Stock Performance
During the last five days, there has been a surge of approximately 4.52%. Over the course of the year, Immunome Inc shares have dropped approximately -15.07%. Shares of the company reached a 52-week high of $12.44 on 02/10/25 and a 52-week low of $5.15 on 04/09/25.
Support And Resistance Levels for Immunome Inc (IMNM)
According to the 24-hour chart, there is a support level at 8.82, which, if violated, would cause prices to drop to 8.62. In the upper region, resistance lies at 9.39. The next price resistance is at 9.76. RSI (Relative Strength Index) is 59.66 on the 14-day chart, showing neutral technical sentiment.
